Michael Feldman
5 Papers
Michael Feldman is an academic researcher. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
The Penn Medicine BioBank: Towards a Genomics-Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse Population
Anurag Verma,Scott M. Damrauer,Nawar Naseer,Jo Ellen Weaver,Colleen M Kripke,L. Guare,Giorgio Sirugo,Rachel L. Kember,Theodore G. Drivas,Scott M. Dudek,Yuki Bradford,Anastasia Lucas,Renae Judy,Shefali S. Verma,Emma A. Meagher,Katherine L. Nathanson,Michael Feldman,Marylyn D. Ritchie,Daniel J. Rader,For The Penn Medicine BioBank +19 more
TL;DR: The Penn Medicine BioBank (PMBB) as mentioned in this paper is an electronic health record (EHR)-linked biobank at the University of Pennsylvania (Penn Medicine), which provides a large variety of health-related information, ranging from diagnosis codes to laboratory measurements, imaging data and lifestyle information, is integrated with genomic and biomarker data to facilitate discoveries and translational science.
Abstract 4648: How inherited mutations affect single cells within the tumor microenvironment in breast tumors stratified by receptor status
Dana Pueschl,Derek A. Oldridge,Jonathan P. Belman,Anupma Nayak,Bradley Wubbenhorst,John Pluta,Michael Feldman,E. John Wherry,Heather Thorne,Georgia Chenevix-Trench,Susan M. Domchek,Katherine L. Nathanson +11 more
TL;DR: Pueschl et al. as discussed by the authors performed a detailed multi-omic single cell analysis of breast cancers with inherited mutations in different genes (BRCA1, BRCA2, PALB2, ATM, CHEK2), and wild type mutation negative (WT) patients, stratified by hormone receptor status, to understand the relationship between inherited mutation and immunogenicity.
Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
Dylane M. Wineland,Anh N Le,Ryan Hausler,Gregory Kelly,Emanuel Barrett,Heena Desai,Bradley Wubbenhorst,John Pluta,Paul Bastian,Heather L. Symecko,Kurt D'Andrea,Abigail Doucette,Peter Gabriel,Kim A. Reiss,Anupma Nayak,Michael Feldman,Susan M. Domchek,Katherine L. Nathanson,Kara N. Maxwell +18 more
TL;DR: Assessment of biallelic loss and HRD could supplement identification of germline BRCA1/2 mutations in selection of patients for platinum or PARP inhibitor therapy.
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
Igor Makhlin,Nicholas P. McAndrew,E. Paul Wileyto,Amy S. Clark,Robin Holmes,Lisa Bottalico,Clementina Mesaros,Ian A. Blair,Grace R. Jeschke,Kevin Fox,Susan M. Domchek,Jennifer M. Matro,Angela R. Bradbury,Michael Feldman,Elizabeth O. Hexner,Jacqueline Bromberg,Angela DeMichele +16 more
TL;DR: In this article , the authors reported the results of a phase 2 single-arm Simon 2-stage trial combining Ruxolitinib, an oral selective inhibitor of JAK1/2, with exemestane, a steroidal AI, in patients with HR+ metastatic breast cancer.
Impact of integrating genomic data into the electronic health record on genetics care delivery.
Kelsey S. Lau-Min,Danielle McKenna,Stephanie Byers Asher,Tanya Bardakjian,Colin Wollack,Joseph Bleznuck,Daniel Biros,Arravinth Anantharajah,Dana Farengo-Clark,Courtney Condit,Jessica Ebrahimzadeh,Jessica M. Long,Jacquelyn Powers,Anna Raper,Anna E Schoenbaum,Michael Feldman,Lauren Steinfeld,Sony Tuteja,Christine VanZandbergen,Susan M. Domchek,Marylyn D. Ritchie,J. M. Landgraf,Jessica Chen,Katherine L. Nathanson +23 more
TL;DR: The PennChart Genomics Initiative's efforts to integrate genomic medicine into the EHR have substantially streamlined the delivery of genomic medicine.